Medtronic announces MiniMed as name for planned New Diabetes Company
GALWAY, Ireland, June 12, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world.
"Our journey began in 1983, when visionary entrepreneur Alfred E. Mann founded MiniMed and revolutionized diabetes care with many first-of-its-kind innovations that pushed the boundaries of care and helped simplify life with diabetes for countless people around the world," said Que Dallara, current EVP and President of Medtronic Diabetes and Chief Executive Officer designate of MiniMed. "We're thrilled to honor this rich 40-year legacy with a name that carries deep meaning and trust. As we step forward into this new and exciting chapter, we'll focus relentlessly on fulfilling our Mission to make diabetes more predictable so everyone can embrace life to the fullest."
Managing diabetes can feel draining and exhausting due to the constant mental and physical demands to keep glucose levels in a healthy range. Every meal and activity requires careful calculation — counting carbs, adjusting insulin, and monitoring levels to prevent dangerous low and high blood sugars that can result in both short- and long-term complications. The company's Mission is inspired by the desire to introduce more stability and predictability with technology that helps push diabetes management into the background.
For many employees, the Mission hits close to home—over 70% of those surveyed have a personal connection to diabetes. That includes Key Payton, who has been with the company for over a decade and was diagnosed with type 1 diabetes in 1960. "When I was just three years old, doctors told my parents I likely wouldn't live past 10. But here I am, 65 years later, defying the odds and living my best life. I've experienced firsthand how the company has transformed diabetes care and personally helped me beat those early odds in astounding ways," said Payton. "I'm forever grateful for the hope and support they've given me every day for nearly three decades. Today, I'm a proud user of the MiniMed™ 780G system,** and my Time in Range § has never been better. I'm finally sleeping through the night and worrying less about my diabetes — it's freeing."
Based in Northridge, California, the Diabetes business is a passionate team of more than 8,000 employees dedicated to pushing the boundaries of innovation, developing breakthrough technologies that reduce burden, enhance quality of life, improve health outcomes, and redefine standards of care.
Medtronic is targeting completion of the planned separation within 18 months of the initial announcement, subject to customary conditions and legal requirements including consultations with works councils and other employee representative bodies.
Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to Medtronic's ability to satisfy the necessary conditions to consummate the separation of its Diabetes business on a timely basis or at all, Medtronic's ability to successfully separate its Diabetes business and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders), MiniMed's ability to succeed as a standalone publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of Medtronic. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. While a split-off is Medtronic's current preferred separation structure, a final decision has not been reached at this time. The separation is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof, of the company's remaining shareholding in MiniMed.
**MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see https://bit.ly/780gRisks
§ Refers to SmartGuard™ feature. Individual results may vary.
Ryan Weispfenning
Investor Relations
+1-763-505-4626
SOURCE Medtronic plc
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
10 hours ago
- Cision Canada
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ , Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Cision Canada
11 hours ago
- Cision Canada
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research Français
VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for patients. Total Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain disorders. Total Grant Awarded: $4,845,000 "This platform represents a critical step toward advancing spinal cord injury research globally," said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. "By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients." "With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience," said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. "By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments." These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. "The UBC neuroscience community is grateful for Brain Canada's continued support," said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. "These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan." Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: "By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives." These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. "Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes."
Globe and Mail
12 hours ago
- Globe and Mail
AI in Remote Patient Monitoring (RPM) Market worth $8,438.5 million by 2030 with 27.5% CAGR
"The AI in remote patient monitoring market is dominated by key players. The major players operating in this market are, Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), OMRON Helathcare, Inc. (Japan), GE HealthCare (US), Biobeat (Israel), Boston Scientific Corporation (US)" Browse 290 market data Tables and 59 Figures spread through 323 Pages and in-depth TOC on "AI in Remote Patient Monitoring (RPM) Market by Component (Device: Wearable, Implantable, Portable; Software, Service), Indication (Cardiac, Neuro, Onco, Diabetes, Sleep, Mental Health), End User (Hospitals, Clinics, Payer), Region - Global Forecast to 2030 The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million in 2023, is forecasted to grow at a robust CAGR of 27.5%, reaching US$1967.7 million in 2024 and an impressive US$8438.5 million by 2030. The growing number of elderly people and the growing need for affordable healthcare solutions are the main factors propelling the AI in remote patient monitoring market. The United Nations Population Fund (UNFPA) predicts people aged 65 and older will grow from 10.3% worldwide population in 2024 to 20.7% by 2074. People aged 65+ will put a high strain on health services since healthcare budgets remain limited. Download PDF Brochure: Browse in-depth TOC on ' Artificial Intelligence in Remote Patient Monitoring Market' 290 - Tables 59 - Figures 323 - Pages By component, the artificial intelligence in remote patient monitoring market has been segmented into devices, software and services. In 2023, devices segment is estimated to hold the largest share of the market for AI in remote patient monitoring. AI-powered wearables like smartwatches and biosensors enable seamless, real-time health tracking, while portable and handheld devices such as AI-driven ECG monitors and glucose meters support remote diagnostics and chronic disease management. In the hospital environment, these stationary devices have helped increase the efficiency of Remote Patient Monitoring by functioning alongside enhanced AI analytics, cloud computing, and the Internet of Medical Things for optimum data transmission. As part of its continued commitment to telehealth and easily available, technologically enabled patient care, the Department of Veterans Affairs (VA) initiated several projects in 2025 to enhance remote patient monitoring (RPM). Among those were contracts to establish systems to allow tracking via telemetry for some 35 VA Medical Centers. By end-user, the global AI in remote patient monitoring market has seen significant growth at a very rapid pace. The patient segment is anticipated to be the biggest driver of growth in this sector. Factors such as the rising prevalence of chronic diseases, growing awareness of personalized healthcare, and increased patient engagement in self-monitoring are driving this growth. By enabling early disease detection, predictive analytics, and real-time monitoring of health, AI improves RPM, reduces hospital stays length, and recommends better patient outcomes. Real-time monitoring of health due to AI, predictive analytics, and early detection of diseases forms RPM to result in reduced hospital stay lengths and improved patient outcomes. AI-powered virtual assistants, digital health platforms, and remote diagnostics allow remote patient monitoring to become easier and more efficient, further boosting the growth of this market. An example is the KardiaRx App developed by AliveCor, Inc. that empowers patients and clinical trial participants to record ECGs at home. By geography, the artificial intelligence in remote patient monitoring market (RPM) is segmented into five major regions: North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. Asia Pacific is expected to register highest growth during the forecast period. Factors which are driving this growth include increased in disposable incomes. Access to healthcare has changed significantly in this region, which is home to two-thirds of the world's population. This is particularly true in nations like China, where 10 million more seniors are added each. The region's governments have started programs to increase gadget manufacturing. India has invested 1,057.47 crore rupees as of September 2024 to construct 50 new manufacturing plants, while construction is underway on another 50. This endeavor is crucial to boosting the nation's ability to produce cutting-edge medical devices and facilitate the use of AI in remote patient monitoring. In order to provide everyone with access to reasonably priced and high-quality RPM and telehealth services, the National Digital Health Mission (NDHM) also seeks to establish a digital health ecosystem. Request Sample Pages: The AI in remote patient monitoring market is dominated by key players. The major players operating in this market are, Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), OMRON Helathcare, Inc. (Japan), GE HealthCare (US), Biobeat (Israel), Boston Scientific Corporation (US), Dexcom, Inc. (US), NIHON KOHDEN CORPORATION (Japan), F. Hoffmann-La Roche Ltd (Roche Diagnostics) (Switzerland), ResMed Inc. (US), AliveCor, Inc. (US), Biotronik (Germany), Beijing Choice Electronic Tech Co. Ltd. (China), TytoCare Ltd. (US), Gloooko, Inc. (US), Welldoc, Inc. (US), Zeto Inc. (US), Turtle Shell Technologies Pvt. Ltd. (Dozee) (India), Masimo (US), iRhythm Inc. (US). Koninklijke Philips N.V. (Netherlands): Koninklijke Philips N.V. is the parent company of the Philips Group. The company works in four areas: Personal Health, Diagnosis and Treatment, Connected Care and Others. Connected Care segments provide Al in Remote Patient Monitoring solutions. Philips has grown over time through collaborations with key partners in the marketplace. In July 2024, the organization partnered with Bon Secours Mercy Health on a short-term initiative that aimed to enhance patient monitoring within 49 hospitals. The objective was to raise care quality while maintaining costs under control. Some of its major subsidiaries are Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands). It spans operations across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Medtronic (Ireland): Medtronic is a global healthcare technology company based in Dublin, Ireland. The company helps healthcare systems, doctors, clinicians, and patients in more than 150 countries worldwide. It operates through four main business areas: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Medtronic offers AI-powered Remote Patient Monitoring solutions across all four of its business segments. Also, approvals and partnerships are being pursued for an expansion of its diabetes device portfolio. In August 2024, Medtronic announced a partnership with Abbott for the integration of continuous glucose monitoring technology to improve diabetes care for the patients. In August 2024, Medtronic introduced the Simplera Continuous CGM and announced the intent for FDA and PMDA approval. The system offers secure near real-time glucose monitoring that helps users to realize better blood sugar control. Boston Scientific Corporation (US): Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates primarily in two business segments, MedSurg and Cardiovascular. The MedSurg segment focuses on endoscopy, urology, and neuromodulation, offering minimally invasive solutions for various medical conditions. The Cardiovascular segment includes interventional cardiology, cardiac rhythm management, electrophysiology, and peripheral interventions, providing technologies for diagnosing and treating heart and vascular diseases. The company provides AI in remote patient monitoring through Cardiovascular segment. Boston Scientific operates in over 40 countries across six continents, with regional headquarters and offices in the North America, Europe, Asia Pacific, Latin America and Middle East and Africa For more information, Inquire Now!
